MSH2 and colorectal carcinoma: The literature reports a wide range of lifetime risks of developing colorectal cancer (CRC) in patients with MLH1 and MSH2 mutations, ranging from 30% to 97% [26,27,28,29,30,31] in male patients, as described by Stoffel and colleagues [32].